Orexo AB represents values of innovation, integrity, and patient-centricity. As a pharmaceutical company, Orexo is dedicated to developing innovative solutions for the treatment of substance abuse and mental health disorders. The company's corporate philosophy revolves around improving the lives of patients by providing safe and effective medications. Orexo prioritizes ethical conduct, ensuring transparency and adhering to strict regulatory standards. Through its research and development efforts, Orexo aims to address unmet medical needs and make a positive impact on society. With its strong values and commitment to patient well-being, Orexo AB continues to be a trusted name in the pharmaceutical industry.

Orexo AB is primarily present in several countries and regions worldwide. The company has a significant presence in Europe, including countries like Sweden, Norway, Denmark, and Finland. Additionally, Orexo AB is expanding its footprint in the United States, where it is steadily growing its market presence. With its innovative pharmaceutical solutions and commitment to improving patient outcomes, Orexo AB is dedicated to reaching more regions and markets in the future.

Orexo AB has achieved several significant milestones since its establishment. The company successfully developed and commercialized Zubsolv®, a sublingual treatment for opioid dependence. Orexo AB also received approval for Abstral®, an innovative sublingual rapid-disintegrating tablet for cancer breakthrough pain management. Additionally, the company has secured partnerships and collaborations with multiple pharmaceutical companies, expanding its global reach and product portfolio. Orexo AB's dedication to research and development has led to the successful launch of pharmaceutical products that address unmet medical needs, reinforcing its position as a leading player in the pharmaceutical industry.

Orexo AB is a pharmaceutical company headquartered in Sweden. Founded in 1995, Orexo has a rich history and background in developing innovative treatments for patients with opioid addiction. The company specializes in creating and commercializing unique medications using its proprietary technologies. With a focus on opioid dependence and pain management, Orexo has established itself as a leading player in the pharmaceutical industry. Orexo AB constantly strives to improve patient outcomes and contribute to the overall well-being of individuals dealing with addiction and pain-related issues.

The main competitors of Orexo AB in the market include pharmaceutical companies such as Indivior PLC, Mallinckrodt Pharmaceuticals, and Teva Pharmaceutical Industries Ltd. These companies also operate in the field of addiction medicine and create products and treatments for substance abuse disorders.

Orexo AB is primarily active in the pharmaceutical industry.

The business model of Orexo AB revolves around the development and commercialization of innovative pharmaceutical products. Orexo focuses on improving the treatment options for patients suffering from opioid dependence and pain management. The company leverages its expertise in formulation technologies and clinical development to create patented products with unique characteristics. Orexo's flagship product, Zubsolv®, is a leading medication for opioid dependence, providing convenient and effective treatment. Through collaborations and strategic partnerships, Orexo aims to expand its product portfolio and geographical presence, delivering value to patients, healthcare professionals, and stakeholders.

Orexo의 P/E 비율은 -2.89입니다.

Orexo의 P/S 비율은 0.58입니다.

Orexo에 대한 AlleAktien 품질 점수는 2/10입니다.

예상되는 Orexo 매출은 592.12 백만 SEK입니다.

예상되는 Orexo 이익은 -119.52 백만 SEK입니다.

Orexo AB is a pharmaceutical company focused on developing innovative medications for the treatment of opioid dependence, pain management, and other diseases. The company was founded in 1995 and is headquartered in Uppsala, Sweden. Orexo AB's business model is based on various divisions that allow the company to market its products at different levels. These divisions include medications for the treatment of opioid dependence, medications for pain management, benefit assessment and market access services, and research and development efforts. The company aims to provide tailored medications and services to meet the needs of patients and healthcare professionals. With its focus on opioid dependence and pain management, Orexo AB is well-positioned to serve a growing demographic and maintain high standards of product safety and quality. The company has a strong history of growth and continues to invest in research and development, making it a significant player in the market for opioid dependence and pain management.

Orexo은(는) 연간 번의 배당을 통해 0 SEK의 배당금을 지급합니다.

Orexo의 현재 배당금은 계산할 수 없거나, 회사가 배당금을 지급하지 않습니다.

Orexo의 ISIN은 SE0000736415입니다.

Orexo의 WKN은 A0HG6G입니다.

Orexo의 티커는 ORX.ST입니다.

지난 12개월 동안 Orexo은(는) 의 배당금을 지급했습니다. 이는 약 의 배당 수익률에 해당합니다. 향후 12개월 동안 Orexo은(는) 0 SEK의 배당금을 지급할 것으로 예상됩니다.

Orexo의 현재 배당 수익률은 입니다.

Orexo은 분기별로 배당금을 지급합니다. 이는 월에 배당됩니다.

Orexo은(는) 지난 0년 동안 매년 배당금을 지급했습니다.

향후 12개월 동안 0 SEK의 배당금이 예상됩니다. 이는 배당수익률 0 %에 해당합니다.

Orexo은 '건강' 섹터에 속합니다.

Orexo의 마지막 배당금을 0 SEK만큼 받기 위해선 의 Ex-Tag 전에 주식을 보유하고 있어야 했습니다.

마지막 배당금 지급일은 입니다.

2023년에 Orexo는 0 SEK를 배당금으로 지급했습니다.

Orexo의 배당금은 SEK에 지급됩니다.